Jeffrey M. Jonas - Oct 19, 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Innovation Officer, Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Stock symbol
SAGE
Transactions as of
Oct 19, 2021
Transactions value $
-$176,228
Form type
4
Date filed
10/21/2021, 04:03 PM
Previous filing
Jun 23, 2021
Next filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +10K +13.29% $0.00 85.2K Oct 19, 2021 Direct F1
transaction SAGE Common Stock Tax liability -$176K -4.37K -5.13% $40.29 80.9K Oct 19, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 10,000 shares.